Invesaro

Stocks SONM Financial statements

Financial statements

DNA X, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data DNA X, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2019FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1361166454.669.893.658.3
Cost of revenue87.681.748.848.258.274.348.4
Gross profit48.134.515.26.4111.619.39.92
Research and development23.226.116.217.77.971.7714.2
Selling and marketing12.213.910.49.577.278.7713
General and administrative7.2215.19.8310.310.78.273.15.41
Operating expenses42.756.944.544.425.918.83.15.41
Operating income5.39-22.4-29.3-38-14.30.51-3.1-5.41
Interest expense0.10.95
Other non-operating income-0.57-0.54-0.43-0.460.48-0.210.25-0.9
Pre-tax income2.03-24.4-30.5-38.5-13.90.28-2.88-7.96
Income tax0.751.39-0.520.170.180.370.23-1.15
Income from continuing operations-2.88-7.96
Net income1.28-25.8-29.9-38.6-14.1-0.09-33.6-20.7
EBITDA7.24-18.9-26.5-35.9-11.92.720.46-1.11
EPS, basic-461.28-249.49-116.67-73.46-8.82-0.36-128.37-28.58
EPS, diluted-461.28-249.49-116.67-73.46-8.82-0.36-128.37-28.58
Shares, basic (weighted)0.020.10.260.531.60.240.260.72
Shares, diluted (weighted)0.020.10.260.531.60.240.260.72

Balance sheet

FY2019FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash and equivalents1311.322.111.213.29.45.341.3
Receivables18.910.14.1510.822.425.34.34
Inventory21.819.511.35.543.916.5210.6
Other current assets1.061.230.810.720.521.614.560.68
Total current assets63.947.345.635.743.643.832.228.9
Property, plant and equipment1.071.440.840.530.170.070.23
Lease right-of-use assets00.070.06
Other non-current assets2.522.972.950.380.27
Total assets67.355.550.341.153.75639.743.9
Accounts payable27.37.238.869.4721.119.80.744.03
Accrued liabilities16.410.39.9111.410.712.30.250.7
Deferred revenue4.220.290.010.010.030.01
Short-term debt0.39.820.180.150.155.07
Total current liabilities48.227.620.52132.132.143.750.6
Long-term debt13.20.360.190.07
Lease liabilities0.07
Total liabilities62.229.921.922.533.633.745.450.6
Total debt13.510.20.360.210.155.07
Paid-in capital149192225253270272278296
Retained earnings-144-166-196-235-250-250-284-304
Shareholders' equity5.1325.528.418.62022.4-5.7-7.96
Total equity5.1325.528.418.62022.4-5.7-7.96
Total liabilities and equity67.355.550.341.153.75639.743.9
Shares outstanding0.090.113.681.042.260.250.281.27

Cash flow statement

FY2019FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income1.28-25.8-29.9-38.6-14.1-0.09-33.6-20.7
Depreciation and amortization1.853.532.732.132.382.213.564.3
Stock-based compensation0.256.311.091.091.551.51.531.54
Deferred income tax0.140.110.02-0.02-0.140.07-0.01-1.43
Change in receivables-8.078.755.92-7.52-11.6-3.037.36-1.11
Change in inventory-12.8-0.817.494.181.63-2.61-4.993.85
Change in payables16-20.21.490.6211.7-1.2814.39.53
Cash from operations3.86-33.5-10.6-38.5-12.4-4.05-8.49-23.5
Capital expenditures-0.79-0.99-0.01-0.05-0.01-0.04-0.21
Cash from investing-2.55-1.36-0.01-0.05-0.01-0.04-0.21
Debt issued4.996.37
Debt repaid-0.22-3.69-4.15-0.15-0.07
Stock issued8.338.525.127.714.40.424.0113.7
Cash from financing10.233.121.427.614.30.274.6519.5
Net change in cash11.5-1.7510.8-10.91.98-3.82-4.05-4.04
Free cash flow3.07-34.5-10.6-38.5-12.4-4.09-8.7
Interest paid0.551.040.260.10.020.030.95
Income taxes paid0.260.270.080.090.150.040.130.12

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.35 on September 28, 2026.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)-189.2%Net income / average total assets.

Growth

MetricValueHow it is calculated
EBITDA growth, 1y-342.0%EBITDA vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y10.5%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y-6.5%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y-2.7%Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y175.7%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y-23.3%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y23.0%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio0.57xCurrent assets / current liabilities.
Quick ratio0.42x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio0.17x(Cash + short-term investments) / current liabilities.
Liabilities / assets127.3%Total liabilities / total assets.
Working capital-$2.2MCurrent assets - current liabilities.
Goodwill and intangibles / assets30.5%(Goodwill + intangible assets) / total assets.
Tangible book value-$2.6MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted-$6.33Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share-$10.74Cash from operations / diluted weighted shares.
Book value per share-$0.83Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$1.75Tangible book value / shares outstanding.
Cash per share$0.60(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$6.5MShare price x shares outstanding.
Enterprise value$5.6MMarket cap + total debt - cash - short-term investments.
Earnings yield-132.0%Net income / market cap (the inverse of P/E).
Was DNA X, Inc. profitable in fiscal 2025?

No. It reported a net loss of $20.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to DNA X, Inc.